Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
100 participants
OBSERVATIONAL
2018-11-15
2021-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Treatment of Pain Associated With Lumbosacral Radiculopathy in Adults
NCT03727100
Sciatica Epidural Radiculopathy Experimental New Interventional TherapY Clonidine Micropellet
NCT05614648
Clonidine-induced Spinal Acetylcholine Release: Normal Volunteers vs. Neuropathic Pain
NCT00350532
Single Ascending Doses Study of KLS-2031 in Subjects With Neuropathic Pain From Lumbosacral Radiculopathy
NCT04238793
Study on the Efficacy of Infiltration of Upper Cluneal Nerves in Chronic Pain Related to Cluneal Syndrome
NCT05423132
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Safety Group
STX-015-18-01 Clonidine Micropellet long-term safety follow-up
Long-Term Safety Follow-up
STX-015-18-01 long-term safety follow-up
Sham Control
STX-015-18-01 Sham control long-term safety follow-up
Long-Term Safety Follow-up
STX-015-18-01 long-term safety follow-up
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Long-Term Safety Follow-up
STX-015-18-01 long-term safety follow-up
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Subjects who were unblinded to their treatment in STX-015-18-01 study.
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sollis Therapeutics, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christopher Gilligan, MD
Role: PRINCIPAL_INVESTIGATOR
Brigham and Women's Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sollis Clinical Study Site 36
Mobile, Alabama, United States
Sollis Clinical Study Site 44
Phoenix, Arizona, United States
Sollis Clinical Study Site 40
Tucson, Arizona, United States
Sollis Clinical Study Site 49
Rancho Mirage, California, United States
Sollis Clinical Study Site 30
Washington D.C., District of Columbia, United States
Sollis Clinical Study Site 35
Fort Lauderdale, Florida, United States
Sollis Clinical Study Site 38
Miami, Florida, United States
Sollis Clinical Study Site 12
Bloomington, Illinois, United States
Sollis Clinical Study Site 13
Chicago, Illinois, United States
Sollis Clinical Study Site 14
Kansas City, Kansas, United States
Sollis Clinical Study Site 37
Overland Park, Kansas, United States
Sollis Clinical Study Site 10
Edgewood, Kentucky, United States
Sollis Clinical Study Site 15
Brookline, Massachusetts, United States
Sollis Clinical Study Site 17
Shrewsbury, New Jersey, United States
Sollis Clinical Study Site 31
Rochester, New York, United States
Sollis Clinical Study Site 18
Winston-Salem, North Carolina, United States
Sollis Clinical Study Site 21
Cleveland, Ohio, United States
Sollis Clinical Study Site 33
Cleveland, Ohio, United States
Sollis Clinical Study Site 19
Edmond, Oklahoma, United States
Sollis Clinical Study Site 46
Eugene, Oregon, United States
Sollis Clinical Study Site 42
Dallas, Texas, United States
Sollis Clinical Study Site 34
Houston, Texas, United States
Sollis Clinical Study Site 47
Salt Lake City, Utah, United States
Sollis Clinical Study Site 23
Morgantown, West Virginia, United States
Sollis Clinical Study Site 27
Madison, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
STX-015-18-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.